组学技术设施-猫眼课题宝

组学技术设施

批准号：

10703083

负责人：

Liang Cao

金额：

$82.28万

依托单位：

DIVISION OF BASIC SCIENCES - NCI

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/10703083

关键词：

ATAC-seq Algorithms Antibodies Area Bioinformatics Biological Biological Assay Biology CCR Cells ChIP-seq Classification Clinical Communities Computational Biology Contractor Cooperative Research and Development Agreement Custom DNA DNA analysis DNA sequencing Data Data Analyses Detection Development Enhancers Epigenetic Process Foundations Funding Gene Rearrangement Genes Genetic Genome Goals Immunogenomics Industrialization Intention Internet Laboratories Left Machine Learning Malignant Neoplasms Mediating Methods Micrococcal Nuclease Molecular Profiling Molecular Target Mutation Detection Oncogenes Positioning Attribute Proteomics Protocols documentation RNA Research Research Personnel Resources Sequence Analysis Structure T-Lymphocyte Technology Training Tumor Antigens United States National Institutes of Health Validation Work assay development base biomarker development clinical biomarkers convolutional neural network epigenetic regulation exome sequencing genome sequencing innovation mass spectrometric imaging member new technology next generation sequencing operation recruit response screening single-cell RNA sequencing targeted sequencing technology development tool transcriptome sequencing tumor whole genome

项目摘要

项目成果

Liang Cao的其他基金

相似基金

相关文献

中文摘要

翻译

由于该项目是在本财政年度启动的，主要工作集中在建立运营和开发核心技术上。A.组队：网络实验室：另外两名成员于22财年4月从之前的Molecular Profile/Clinomics Core转移到我们这里，其中一名已于6月22日离开NCI。我们将在23财年填补这个空缺位置。2. IT团队：两名成员通过NCI Frederick承包商被招募到IT团队。这个IT团队目前正在帮助建立下一代测序（NGS）数据分析的管道。B.核心技术开发。我们主要致力于建立基于ngs的技术，以发现癌症驱动因素，并了解生物机制。具体而言，下列技术已确立或接近确立。1. NGS用于癌症突变检测。我们采用了DNA和RNA外显子组测序的方法，目的是检测SNV、缺失和插入。2. NGS用于表达和融合检测。实验室的工作人员接受了RNA外显子组测序的培训，用于检测融合和表达分析。3. 表观遗传调控。我们采用了两种不同的chip-seq方法，包括通过微球菌核酸酶和转座进行抗体介导的DNA切割。4. 癌症基因面板的靶向测序t细胞介导的肿瘤抗原应答相关基因的定制检测开发和测序分别对NGS方法的预期研究或临床应用进行验证完善NGS数据分析的分析管道

英文摘要

As the project was started in this fiscal year, the main effort was focused on the establishment of operation and in the development of core technologies. A. Team formation: 1. Web lab: Two additional members were transferred to us in April of FY22 from the previous Molecular Profile/Clinomics Core, one of which had since left NCI in June 22. We'll fill in this vacate position in FY23. 2. IT team: Two members were recruited to the IT team via the NCI Frederick contractor. This IT team is currently helping to establish the pipelines for Next Generation Sequencing (NGS) data analysis. B. Core technology development. We are mainly focused on establishing NGS-based technologies for discovery cancer drivers, and for understanding biological mechanisms. Specifically, the following technologies are established or near establishment. 1. NGS for cancer mutation detection. We adapted methods for both DNA and RNA Exome sequencing aimed for detection SNV, deletion, an insertion. 2. NGS for expression and fusion detection. The staff in the lab were trained for RNA Exome seq for the detection of fusions, and for expression analysis. 3. Epigenetic regulation. We adapted two different methods for chip-seq, including antibody-mediated DNA cutting by micrococcal nucleases and transposes. 4. Targeted sequencing of cancer gene panels 5. Customized assay development and sequencing of genes involved in T-cell mediated responses against tumor antigens 6. Validation of the NGS methods for their intended research or clinical use, respectively 7. Refining the analytical pipelines for NGS data analysis

期刊论文(0)

专著(0)

科研奖励(0)

会议论文